Liao Cheng-Hsi, Chang Wen-Shin, Hu Pei-Shin, Wu Hsi-Chin, Hsu Shih-Wei, Liu Yen-Fang, Liu Shih-Ping, Hung Huey-Shan, Bau DA-Tian, Tsai Chia-Wen
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
In Vivo. 2017 Jul-Aug;31(4):631-635. doi: 10.21873/invivo.11104.
BACKGROUND/AIM: Mounting evidence has suggested that polymorphisms in the promoters of matrix metalloproteinase (MMP) genes are associated with the risk of many types of cancer, but no study has ever explored these polymorphisms as biomarkers for renal cell cancer (RCC). Recently, it was suggested that serum MMP-7 levels have both diagnostic and prognostic potential for RCC. In this study, we focused on the contribution of two functional polymorphisms in the promoter region of MMP-7 (A-181G and C-153T) to RCC.
These two polymorphisms were genotyped in 92 patients with RCC and 580 controls by PRC-RFLP analysis.
The results showed that there is no significant association of the RCC risk with the MMP-7 A-181G genotype, even after adjusted for the possible confounding factors. The MMP-7 C-153T polymorphism was not identified among the subjects investigated.
Our findings suggest that the two MMP-7 polymorphisms A-181G and C-153T do not play a major role in determining personal susceptibility to RCC in Taiwan.
背景/目的：越来越多的证据表明，基质金属蛋白酶（MMP）基因启动子多态性与多种癌症风险相关，但尚无研究探讨这些多态性作为肾细胞癌（RCC）生物标志物的情况。最近，有人提出血清MMP-7水平对RCC具有诊断和预后潜力。在本研究中，我们聚焦于MMP-7启动子区域两个功能性多态性（A-181G和C-153T）对RCC的影响。
通过聚合酶链反应-限制性片段长度多态性（PRC-RFLP）分析对92例RCC患者和580例对照进行这两个多态性的基因分型。
结果显示，即使在对可能的混杂因素进行校正后，RCC风险与MMP-7 A-181G基因型之间也无显著关联。在所研究的受试者中未发现MMP-7 C-153T多态性。
我们的研究结果表明，MMP-7的两个多态性A-181G和C-153T在决定台湾地区个人对RCC的易感性方面不发挥主要作用。
